ALK raises 2026 outlook on strong tablet sales

Gothenburg-based OnDosis has entered a strategic collaboration with Adare Pharma Solutions, a US contract development and manufacturing organization (CDMO), to advance its lead ADHD program toward the US market. The partnership gives OnDosis commercial-scale manufacturing capacity in the US.

Health Canada has approved Camurus’s Oczyesa XR, a once-monthly subcutaneous octreotide depot, for maintenance treatment of adults with acromegaly who have responded to and tolerated treatment with somatostatin analogs.

Finnish clinical-stage biotech Desentum has closed an oversubscribed EUR 28 million equity round to advance its allergy vaccines.

Orexo's board has resolved on a rights issue of about SEK 250 million, subject to approval at an extraordinary general meeting on November 6. The money is mainly for the company's development programs, including the first pivotal trial of OX640.

Finnish Orion Pharma has signed an agreement with Qilu Pharma Europe for a pembrolizumab biosimilar for the European market. A day earlier, it dosed the first patient with ODM-216, its first biologic drug candidate to reach clinical testing.

Bavarian Nordic has raised its full-year 2026 guidance for the third time this year. It now expects revenue of about DKK 6,100 million, up from about DKK 5,700 million, driven by higher sales of rabies vaccines, mainly in the US.

Norwegian Prime Minister Jonas Gahr Støre will officially open Thor Medical's AlphaOne production facility at Herøya Industrial Park on October 19. The Oslo-based company supplies high-purity alpha-emitting isotopes to the radiopharmaceutical industry.